Kfar Hahoresh, Israel

Dana Fuchs Telem

This inventor holds 1 USPTO granted patent. Top assignee: Pluristem Ltd.. Active years: 2019.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dana Fuchs Telem: Innovator in Muscle Wasting Treatment

Introduction

Dana Fuchs Telem is an accomplished inventor based in Kibbutz Kfar Hahoresh, Israel. He has made significant contributions to the field of medical science, particularly in the treatment of muscle wasting disorders. His innovative approach has the potential to improve the quality of life for many individuals suffering from these conditions.

Latest Patents

Dana Fuchs Telem holds a patent for "Methods and compositions for treating and preventing muscle wasting disorders." This patent describes methods of treating and preventing muscle wasting and muscle loss, utilizing adherent stromal cells and the conditioned medium produced from them. This groundbreaking work highlights the importance of cellular therapies in addressing muscle-related health issues.

Career Highlights

Throughout his career, Dana has been associated with Pluristem Ltd., a company known for its advancements in cell therapy. His work at Pluristem has allowed him to collaborate with leading experts in the field and contribute to innovative solutions for muscle wasting disorders.

Collaborations

Dana has worked alongside talented colleagues, including Esther Lukasiewicz Hagai and Rachel Ofir. Their combined expertise has fostered a collaborative environment that encourages innovation and the development of effective treatments.

Conclusion

Dana Fuchs Telem's contributions to the field of muscle wasting treatment exemplify the impact of innovative thinking in medical science. His patent and work at Pluristem Ltd. represent significant advancements that could change the landscape of treatment for muscle-related disorders.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…